Pathways Involved in the Effect of Eflornithine in Neuroblastoma

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons. October 26, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01783 Journal of Clinical Oncology - published online before print October 26, 2023 PMID: 37883720 Pathways Involved in the Effect of Eflornithine in Neuroblastoma Adam J. Wolpaw , MD, PhD1xAdam J. WolpawSearch for articles by this author and Chi V. Dang , MD, PhD2,3,4,5,6xChi V. DangSearch for articles by this author Show More 1Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD3Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD4Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD5Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD6Ludwig Institute for Cancer Research, New York, NY https://doi.org/10.1200/JCO.23.01783 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTSupported in part by NCI grants R01CA252225 (C.V.D.), R01CA051497 (C.V.D.), K08CA266914 (A.J.W.), and R01CA057341 (C.V.D.), Johns Hopkins Bloomberg Distinguished Professorship (C.V.D.), and the Ludwig Institute for Cancer Research (C.V.D.). C.V.D. is a consultant for Geneos Pharm and Cornerstone Pharm.AUTHOR CONTRIBUTIONSConception and design: All authorsFinancial support: Adam J. WolpawProvision of study materials or patients: Chi V. DangData analysis and interpretation: Chi V. DangManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTPathways Involved in the Effect of Eflornithine in NeuroblastomaThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Chi V. DangPatents, Royalties, Other Intellectual Property: I am coinventor of a patent for a lactate dehydrogenase small molecule inhibitor. I have a small royalty of a mammalian 2-hybrid assay licensed by Johns Hopkins University to PromegaNo other potential conflicts of interest were reported. Companion Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons